Treatment Archives – Page 5 of 11 – Treatment Action Group

Treatment Action Group Statement: U.S. District Court Ruling Allowing Employers to Deny PrEP Coverage Is a Dangerous Attack on Public Health

October 6, 2022
Dorrit Walsh

Treatment Action Group (TAG) unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

August 1, 2022
Dorrit Walsh

We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

U.S. Government Funded Research Brings Shorter Tuberculosis Treatment Regimens to New York City

May 16, 2022
Dorrit Walsh

We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB).

Test and Treat COVID-19: Community Guide to Molnupiravir

April 20, 2022
Dorrit Walsh

This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about molnupiravir: what it is, how to take it, who should use it (and who should not,) and how it interacts with other drugs.

cover of: Test and Treat Mild or Moderate COVID-19: Paxlovid (nirmatrelvir/ritonavir)

Test and Treat COVID-19: Community Guide to Paxlovid

April 11, 2022
Dorrit Walsh

Paxlovid can reduce the risk of hospitalization or death by 89% when taken shortly after testing positive for COVID-19. This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about Paxlovid: what it is,…

HIV Updates From CROI: The Good, the Bad, and the Long-Acting

March 29, 2022
Dorrit Walsh

On April 15 TAG presented, "HIV Updates From CROI: The Good, the Bad, and the Long-Acting." This free webinar unpacked the most significant developments in HIV research presented at the Conference on Retroviruses and Opportunistic Infection (CROI), and what they mean for communities affected by HIV.

CROI 2022 TB Round Up

March 22, 2022
Dorrit Walsh

Treatment Action Group welcomes the tuberculosis (TB) data reported at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI). This is a summary of major findings — and TAG’s take on them.

The Right to Prevent TB

March 17, 2022
Dorrit Walsh

It’s now easier than ever to prevent TB before it develops into active disease or spreads within communities.

Talk About It with TAG: The Impact of Long COVID on People Living With HIV

March 3, 2022
Dorrit Walsh

On March 3, 2022, we presented the first "Talk About It with TAG" webinar. This series addresses the needs of community members by having open discussions with researchers and community experts on issues related to COVID-19 and HIV biomedical research.

Statement from TAG’s HIV Project on FDA’s Approval of Injectable Pre-Exposure Prophylaxis

December 22, 2021
Dorrit Walsh

Treatment Action Group (TAG) welcomes and celebrates the U.S. Food and Drug Administration’s (FDA) approval of Apretude brand cabotegravir, the first injectable medication for use as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission.